Karyopharm Therapeutics INC 8-K filings

Karyopharm Therapeutics' Executive Vice President, CFO, and Treasurer, Michael Mason, will resign on November 5, 2024, with a transition agreement in place.

Karyopharm Therapeutics announced its second quarter 2024 financial results, highlighted by revenue growth and positive clinical trial updates, along with an improved financial outlook.

Karyopharm Therapeutics' stockholders approved amendments to the company's equity incentive and employee stock purchase plans, along with the election of three Class II directors at the 2024 Annual Meeting.

Karyopharm Therapeutics has finalized an agreement for the issuance of $115.978 million in convertible senior notes due in 2029, outlining the terms and conditions of the debt.

Karyopharm Therapeutics has successfully refinanced a significant portion of its debt, extending maturities to 2028 and 2029, and reducing its obligations to HealthCare Royalty Management.

Karyopharm Therapeutics announced its first quarter 2024 financial results, highlighted by a significant refinancing transaction and progress in clinical development programs.

Karyopharm Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting a decrease in XPOVIO sales but anticipating key clinical trial readouts in 2025.

Karyopharm Therapeutics has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.